Bibliography
- von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009;121:227-52
- DeBoer MD. Update on melanocortin interventions for cachexia: progress toward clinical application. Nutrition 2010;26:146-51
- Farooqi IS, Keogh JM, Yeo GS, Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003;348:1085-95
- Markison S, Foster AC, Chen C, The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 2005;146:2766-73
- Krakoff J, Ma L, Kobes S, Lower metabolic rate in individuals heterozygous for either a frameshift or a functional missense MC4R variant. Diabetes 2008;57:3267-72
- Weyermann P, Dallmann R, Magyar J, Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One 2009;4:e4774
- Peter JC, Bekel A, Lecourt AC, Anti-melanocortin-4 receptor autoantibodies in obesity. J Clin Endocrinol Metab 2009;94:793-800
- Hofbauer KG, Lecourt AC, Peter JC. Antibodies as pharmacologic tools for studies on the regulation of energy balance. Nutrition 2008;24:791-7
- Lee AH, Mull RL, Keenan GF, Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994;96:35-41
- Zimmers TA, Davies MV, Koniaris LG, Induction of cachexia in mice by systemically administered myostatin. Science 2002;296:1486-8
- Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res 2006;53:482-91
- Lamont LS, Brown T, Riebe D, Caldwell M. The major components of human energy balance during chronic beta-adrenergic blockade. J Cardiopulm Rehabil 2000;20:247-50
- Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer 2005;93:425-34
- von Haehling S, Sandek A, Anker SD. Pleiotropic effects of angiotensin-converting enzyme inhibitors and the future of cachexia therapy. J Am Geriatr Soc 2005;53:2030-1
- Anker SD, Lechat P, Dargie HJ. Prevention and reversal of cachexia in patients with chronic heart failure by bisoprolol: results from the CIBIS II-study [abstract]. J Am Coll Cardiol 2003;41:156A-7A
- Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004;90:464-70
- von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-alpha and the failing heart - pathophysiology and therapeutic implications. Basic Res Cardiol 2004;99:18-28
- von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol 2002;85:173-83
- Kojima M, Hosoda H, Date Y, Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60
- Date Y, Kojima M, Hosoda H, Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000;141:4255-61
- Muscaritoli M, Anker SD, Argilés J, Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 2010. DOI:10.1016/j.clnu.2009.12.004
- Janssen I, Baumgartner RN, Ross R, Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 2004;159:413-21
- Pfeifer M, Begerow B, Minne HW, Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int 2009;20:315-22
- Evans WJ, Morley JE, Argilés J, Cachexia: a new definition. Clin Nutr 2008;27:793-9